86Y-DOTA0-D-Phe1-Tyr3-octreotide (SMT487) - A phase 1 clinical study: Pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 4, 2003, Pages 510-518

  Jamar, François ^a   Barone, Raffaella ^a   Mathieu, Isabelle ^a   Walrand, Stéphan ^a   Labar, Daniel ^a   Carlier, Pascal ^a   De Camps, Joëlle ^a   Schran, Horst ^b   Chen, TianLing ^b   Smith, M Charles ^b   Bouterfa, Hakim ^b   Valkema, Roelf ^c   Krenning, Eric P ^c   Kvols, Larry K ^d   Pauwels, Stanislas ^a  

^a UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Amino acids; Peptide based radiotherapy; Renal protection

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AMINO ACID; ARGININE; KIDNEY PROTECTIVE AGENT; LYSINE; OCTREOTIDE; OCTREOTIDE[1 DEXTRO PHENYLALANINE 3 TYROSINE DOTA YTTRIUM 86]; PROTECTIVE AGENT; SMT 487; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; YTTRIUM; YTTRIUM 86; (DOTA(0) PHE(1) TYR(3))OCTREOTIDE; (DOTA(0)-PHE(1)-TYR(3))OCTREOTIDE; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; RADIOPROTECTIVE AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DOSIMETRY; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG UPTAKE; FEMALE; HUMAN; HYPERKALEMIA; KIDNEY CLEARANCE; KIDNEY TUBULE ABSORPTION; MALE; MEAN RESIDENCE TIME; NAUSEA; NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; VERTIGO; VOMITING; ANTIBODY SPECIFICITY; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIZZINESS; DRUG COMBINATION; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MIDDLE AGED; RADIATION DOSE; RADIATION INJURY; RADIOMETRY; SCINTISCANNING; TISSUE DISTRIBUTION; URINE;

ADULT; AGED; AMINO ACIDS; ARGININE; COHORT STUDIES; CROSS-OVER STUDIES; DIZZINESS; DRUG COMBINATIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; LYSINE; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGAN SPECIFICITY; RADIATION DOSAGE; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOMETRY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; VOMITING; YTTRIUM RADIOISOTOPES;

EID: 0037993795     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1117-1     Document Type: Article

References (31)

1. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Rev 1991; 12:450-482.
2. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995; 36:1825-1835.
3. 1]-octreotide. A case history. Ann N Y Acad Sci 1994; 733:496-506.
4. Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, De Herder WW, Stridsberg M, Lindemans J, Ensing G, Krenning EP. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002; 32:110-122.
5. 111Inpentetreotide: initial observations and future directions. Cancer J Sci Am 1998; 4:94-102.
6. Stolz B, Smith-Jones P, Albert R, Albert R, Tolcsvai L, Briner U, Ruser G, Mäcke H, Weckbecker G, Bruns C. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer. Digestion 1996; 57(Suppl 1):17-21.
7. 90Y-SMT487) eradicates experimental rat pancreatic CA 20948 tumors. Eur J Nucl Med 1998; 25:668-674.
8. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin analogue for cancer treatment. Lancet 1998; 351:417-418.
9. 90Y-DOTATOC. J Nucl Med 2002; 43:610-616.
10. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med in press; DOI 10.1007/s00259-002-1023-y.
11. Otte A, Hermann R, Heppeler A, Béhé M, Jermann E, Powell P, Maecke HR, Muller J. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999; 26:1439-1447.
12. de Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002; 32:133-140.
13. 90Y-DOTATOC. Eur J Nucl Med 2001; 28: 1552-1554
14. 1-octreotide in vivo. Bioconjug Chem 1998; 9:662-670.
15. Hammond PJ, Wade AF, Gwilliam ME, Peters AM, Myers MJ, Gilbey SG, Bloom SR, Calam J. Amino acid infusion blocks renal tubular uptake of an indium-labeled somatostatin analogue. Br J Cancer 1993; 67:1437-1439.
16. Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, Mäcke H, de Jong M.d-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997; 38:1929-1933.
17. de Jong M, Rolleman EJ, Bernard BF, Visser TJ, Bakker WH, Breeman WA, Krenning EP. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996; 37:1388-1392.
18. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998; 25:201-212.
19. Rolleman EJ, Valkema R, de Jong M, Kooij PPM, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med 2003; 30:9-15.
20. 90Y-labelled analogue. Eur J Nucl Med 1999; 26:358-366.
21. 111In-DTPA-octreotide. Eur J Nucl Med 2001; 28:1743-1750.
22. Rösch F, Qaim SM, Stöcklin G. Production of the positron emitting radioisotope86Y for nuclear medical applications. Int J Appl Radiat Isot 1993; 44:677-681.
23. Wienhard K, Dahlbom M, Eriksson L, Michel C, Bruckbauer T, Pietrzyk U, Heiss WD. The ECAT EXACT HR: performance of a new high-resolution positron scanner. J Comput Assist Tomogr 1994; 18:110-118.
24. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 1994; 13:601-609.
25. Walrand SH, Jamar F, Mathieu I, De Camps J, Lonneux M, Sibomana M, Labar D, Michel C, Pauwels S. Quantification in PET using isotopes emitting prompt single gammas: application to yttrium-86. Eur J Nucl Med in press. DOI 10.1007/s00259-002-1068-y.
26. ICRP Publication 41. Radiation protection. Nonstochastic effects of ionizing radiation. New York: Pergamon Press, 1991.
27. Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis SM, Najean Y. Interpretation of measured red cell mass and plasma volume in adults. Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995; 89:748-756.
28. 90Y-DOTATOC. Eur J Nucl Med 1999; 26:877-886.
29. 3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997; 24:368-371.
30. 3-octreotide (SMT487). J Nucl Med 2000; 41(Suppl):260P.
31. Mogensen CE, Sølling K. Studies on renal tubular protein re-absorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 1977; 33:477-486.